Authors | Graham P Collins, Toby A Eyre, Kim M Linton, John Radford, Grant D Vallance, Elizabeth Soilleux, Chris Hatton |
Journal | British journal of haematology
(Br J Haematol)
Vol. 170
Issue 6
Pg. 886-90
(Sep 2015)
ISSN: 1365-2141 [Electronic] England |
PMID | 25721307
(Publication Type: Clinical Trial, Phase II, Letter, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate
- Antineoplastic Agents
- Organophosphates
- Protein Kinase Inhibitors
- Quinazolines
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage, adverse effects, therapeutic use)
- Female
- Humans
- Lymphoma, Large B-Cell, Diffuse
(drug therapy, pathology)
- Male
- Middle Aged
- Organophosphates
(administration & dosage, adverse effects, therapeutic use)
- Protein Kinase Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Quinazolines
(administration & dosage, adverse effects, therapeutic use)
- Recurrence
- Treatment Outcome
|